Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.

Circulation. Cardiovascular interventions·2020
Same author

Machine learning to predict venous thrombosis in acutely ill medical patients.

Research and practice in thrombosis and haemostasis·2020
Same author

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.

JAMA cardiology·2020
Same author

Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation.

Journal of thrombosis and thrombolysis·2020
Same author

Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.

Journal of the American College of Cardiology·2020
Same author

The AngelMed Guardian<sup>®</sup> System in the Detection of Coronary Artery Occlusion: Current Perspectives.

Medical devices (Auckland, N.Z.)·2020

相关实验视频

Updated: Jun 3, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

心脏生物标志物的性别差异表达在患有不稳定胸痛/非ST升高心肌梗塞的患者中:TACTICS-TIMI 18 (用Aggrastat治疗胸痛并确定使用侵入性或保守策略治疗的成本-心肌梗塞中的血栓溶解 18) 副研究.

Stephen D Wiviott1, Christopher P Cannon, David A Morrow

  • 1Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, Mass 02115, USA. swiviott@partners.org

Circulation
|February 11, 2004
PubMed
概括

心脏生物标志物模式在不稳定性心痛 (UA) /非ST段升高心肌梗塞 (NSTEMI) 中因性别而异. 多标志物方法可以改善UA/NSTEMI妇女的风险评估.

更多相关视频

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

相关实验视频

Last Updated: Jun 3, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

科学领域:

  • 心脏病学 心脏病学
  • 生物标志物研究 生物标志物研究
  • 医学中的性别差异.

背景情况:

  • 在女性中诊断冠状动脉疾病存在挑战,原因是不太具体的症状和非侵入性测试的诊断准确性较低.
  • 在患有不稳定性胸痛 (UA) 或非ST段升高心肌梗塞 (NSTEMI) 的患者中,研究了心脏生物标志物概况的性别特异性差异.

研究的目的:

  • 检查UA/NSTEMI患者的性别与心脏生物标志物的表现之间的关系.
  • 评估多标志物方法在这种患者群体中风险分层的有用性.

主要方法:

  • 来自三项大型临床研究 (TACTICS-TIMI 18,OPUS-TIMI 16,TIMI 11) 的基线生物标志物数据的分析.
  • 在男性和女性之间比较肌酸激酶-MB,热素,高灵敏性C反应蛋白和大脑性尿素的水平.
  • 评估了单个和多个生物标志物的预后价值.

主要成果:

  • 与男性相比,女性的肌酸激酶-MB或热因水平较低,但更有可能出现高灵敏度C反应蛋白或大脑尿性的升高.
  • 个体标志物的预后值在两性之间是相似的.
  • 一种多标志物方法确定了更高比例的高风险女性.
  • 标志物阳性患者从侵入性策略中受益,而标志物阴性女性在保守的方法中表现出更好的结果.

结论:

  • 在UA/NSTEMI的男性和女性中,心脏生物标志物升高的明显模式存在.
  • 一个多标志物策略可以提高UA/NSTEMI的初始风险评估,特别是在女性中.
  • 需要进一步的研究来了解急性冠状动脉综合征中潜在的与性别相关的病理生理差异.